Flag of the European Union EU Clinical Trials Register Help

Clinical trials for ATE

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    20 result(s) found for: ATE. Displaying page 1 of 1.
    EudraCT Number: 2009-013342-92 Sponsor Protocol Number: DSE-OLM-01-09 Start Date*: 2010-06-08
    Sponsor Name:DAIICHI SANKYO EUROPE GmbH
    Full Title: EFFECTS OF ANGIOTENSIN-RECEPTOR BLOCKADE WITH OLMESARTAN ON CAROTID ATHEROSCLEROSIS IN PATIENTS WITH HYPERTENSION: THE CONFIRMATORY OLMESARTAN PLAQUE REGRESSION STUDY (CONFIRM)
    Medical condition: Essential hypertension in subjects with documented carotid atherosclerosis
    Disease: Version SOC Term Classification Code Term Level
    12.0 10020772 Hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Prematurely Ended) IT (Prematurely Ended) CZ (Completed) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-002139-15 Sponsor Protocol Number: 10660/13 Start Date*: 2013-12-18
    Sponsor Name:POLICLINICO GEMELLI
    Full Title: STUDY COMPARING LIQUID FORMULATION OF LEVOTHYROXINE AND SOLID FORMULATION OF LEVOTHYROXINE ON THE STATE OF WELL- BEING QUALITY OF LIFE AND THE HORMONAL AND METABOLIC PARAMETERS IN THYROIDECTOMIZED ...
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004863 10036429 Postsurgical hypothyroidism LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-003351-37 Sponsor Protocol Number: I4V-MC-JAJA Start Date*: 2019-08-08
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized, Active Controlled, Parallel Group, Phase 3b/4 Study of Baricitinib in Patients with Rheumatoid Arthritis.
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    21.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Trial now transitioned) NL (Trial now transitioned) HU (Completed) DE (Restarted) GR (Trial now transitioned) AT (Trial now transitioned) DK (Trial now transitioned) BE (Trial now transitioned) PL (Trial now transitioned) CZ (Trial now transitioned) LT (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-004437-18 Sponsor Protocol Number: 2343453 Start Date*: 2006-07-18
    Sponsor Name:Department of Otolaryngology, Head and Neck Surgery Johannes Gutenberg-Universität Mainz
    Full Title: Placebo-controlled double-blind study about the effectiveness of longtime acetylsalicylic acid desactivation therapy as prevention of recurrens of poyposis nasi in case of acetylsalicylic acid int...
    Medical condition: chronic rhinosinusistis, polyposis nasi, aspirin intolerance
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-024552-28 Sponsor Protocol Number: 1 Start Date*: 2012-12-03
    Sponsor Name:Oxford Radcliffe Hospitals NHS Trust
    Full Title: BRUISE CONTROL : BRidge or continUe coumadIn for device SurgEry randomized CONTROLled Trial
    Medical condition: The primary study endpoint is the risk of haematoma formation with cardiac device operation using either warfarin anticoagulation or heparin
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-012231-15 Sponsor Protocol Number: ML22608 Start Date*: 2009-11-10
    Sponsor Name:Roche Pharma AG
    Full Title: Pharmacokinetics of Mycophenolate Mofetil in de novo lung allograft recipients
    Medical condition: Prevention of acute allograft rejections in de novo lung allograft recipients
    Disease: Version SOC Term Classification Code Term Level
    12.0 10051604 Lung transplant rejection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-004986-38 Sponsor Protocol Number: 337HNAS20011 Start Date*: 2022-01-04
    Sponsor Name:Inventiva S.A.
    Full Title: A randomised, double-blind, placebo-controlled, multicentre, Phase 3 study evaluating long-term efficacy and safety of lanifibranor in adult patients with non-cirrhotic non-alcoholic steatohepatiti...
    Medical condition: Non-alcoholic Steatohepatitis (NASH)
    Disease: Version SOC Term Classification Code Term Level
    22.0 10019805 - Hepatobiliary disorders 10053219 Non-alcoholic steatohepatitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) ES (Ongoing) AT (Completed) HU (Trial now transitioned) BG (Trial now transitioned) IT (Trial now transitioned) NL (Trial now transitioned) PL (Trial now transitioned) BE (Trial now transitioned) PT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-006809-29 Sponsor Protocol Number: N21CCI Start Date*: 2022-05-23
    Sponsor Name:NKI-AVL
    Full Title: Body surface area-based vs concentration-based dosing of cisplatin for hyperthermic intraperitoneal chemotherapy (HIPEC) in women with advanced ovarian cancer
    Medical condition: FIGO stage III high grade serous ovarian cancer, peritoneal cancer, or fallopian tube carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-001630-21 Sponsor Protocol Number: BAY59-7939/39039039STM4001/18262 Start Date*: 2015-12-15
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism
    Medical condition: Venous thromboembolism (VTE)
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004866 10066899 Venous thromboembolism LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) DE (Completed) CZ (Completed) BG (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-004960-12 Sponsor Protocol Number: VEMUPERTRIAL Start Date*: 2016-05-17
    Sponsor Name:INTERGRUPPO MELANOMA ITALIANO
    Full Title: SEQUENTIAL THERAPY WITH VEMURAFENIB AND ELECTROCHEMOTHERAPY FOR IN-TRANSIT MELANOMA METASTASES: A MULTICENTER SINGLE ARM PHASE II CLINICAL PROSPECTIVE STUDY OF THE ITALIAN MELANOMA INTERGROUP (IMI)
    Medical condition: melanoma BRAF V600 mutated
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027480 Metastatic malignant melanoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-001839-77 Sponsor Protocol Number: 5mille_CT1 Start Date*: 2022-04-26
    Sponsor Name:IRCCS MATERNO INFANTILE BURLO GAROFOLO
    Full Title: A Multicentric, Drug-Repositioning, Self Controlled Case Series (SCCS) Clinical Trial to Evaluate the Efficacy and Safety of Perampanel in Improving Behavioral Symptoms and Increasing the Quality o...
    Medical condition: Patients with POGZ related disorder
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10037173 Psychiatric and behavioural symptoms NEC HLGT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-002147-28 Sponsor Protocol Number: CT-P16_3.1 Start Date*: 2018-12-10
    Sponsor Name:CELLTRION, Inc.
    Full Title: A Double-Blind, Randomized, Active-Controlled, Parallel-Group, Phase 3 Study to Compare Efficacy and Safety of CT-P16 and EU-Approved Avastin as First-Line Treatment for Metastatic or Recurrent Non...
    Medical condition: Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10079440 Non-squamous non-small cell lung cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed) HU (Completed) BG (Completed) PL (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2014-002335-34 Sponsor Protocol Number: STRiVE Start Date*: 2014-10-30
    Sponsor Name:Guy's and St Thomas NHS Foundation Trust
    Full Title: A multicentre randomiSed controlled TRial of IntraVEnous immunoglobulin (IVIg) versus standard therapy for the treatment of transverse myelitis in adults and children
    Medical condition: Transverse myelitis (TM) (acute, first onset cases), including first presentation of neuromyelitis optica (NMO)
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029205 - Nervous system disorders 10028527 Myelitis transverse PT
    17.1 10029205 - Nervous system disorders 10029322 Neuromyelitis optica PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2022-001534-11 Sponsor Protocol Number: GIT-PRo-2022-02 Start Date*: 2022-10-11
    Sponsor Name:Grupo Gallego de Investigación en Tumores Digestivos (GITuD)
    Full Title: Prophylaxis of venous thromboembolic disease with LMWH (TINzaparin) in patients with metastatic colorectal cancer who start the first line of treatment.
    Medical condition: Metastatic colorectal cancer (mCRC), stage IV that initiates the first-line systemic treatment in the metastatic setting
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10010035 Colorectal cancer stage IV PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052358 Colorectal cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-001272-37 Sponsor Protocol Number: 0173 Start Date*: 2019-01-10
    Sponsor Name:Theravance Biopharma Ireland Limited
    Full Title: A Phase 2 Multi-Center, Randomized, Double-Blind, Placebo-controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Induction Therapy with 2 Doses of TD-1473 in Subjects with Moderate...
    Medical condition: Moderately-to-Severely Active Crohn’s Disease (CD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004856 10013099 Disease Crohns LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended) DE (Prematurely Ended) PT (Completed) ES (Prematurely Ended) HU (Prematurely Ended) BG (Completed) AT (Prematurely Ended) GB (GB - no longer in EU/EEA) PL (Ongoing) GR (Completed) HR (Prematurely Ended) RO (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-004845-25 Sponsor Protocol Number: BO29561 Start Date*: 2016-08-23
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: A phase Ib/II study evaluating the safety and efficacy of obinutuzumab in combination with atezolizumab plus polatuzumab vedotin in patients with relapsed or refractory follicular lymphoma and ritu...
    Medical condition: Follicular Lymphoma (FL) or Diffuse Large B-cell Lymphoma (DLBCL)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10016904 Follicle centre lymphoma, follicular grade I, II, III NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2009-016522-14 Sponsor Protocol Number: 20090160 Start Date*: 2011-07-14
    Sponsor Name:Amgen Inc
    Full Title: A Multicenter, Randomised, Double-blind, Placebo-controlled Study of Darbepoetin alfa for the Treatment of Anaemic Subjects with Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
    Medical condition: Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004851 10028536 Myelodysplastic syndromes HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) ES (Completed) BE (Completed) GR (Completed) DE (Completed) IT (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2013-003127-11 Sponsor Protocol Number: CQVA149A3401 Start Date*: 2014-02-26
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A prospective, multicenter, 12-week, randomized open-label study to evaluate the efficacy and safety of glycopyrronium (50 micrograms o.d.) or indacaterol maleate and glycopyrronium bromide fixed-d...
    Medical condition: Chronic obstructive pulmonary disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) LT (Completed) SK (Completed) BE (Completed) EE (Completed) LV (Completed) IE (Completed) SE (Completed) AT (Completed) PT (Completed) IT (Completed) GB (Completed) DK (Completed) GR (Completed) HU (Completed) PL (Completed) ES (Completed) DE (Completed) SI (Completed)
    Trial results: View results
    EudraCT Number: 2013-002513-35 Sponsor Protocol Number: CRLX030A3301 Start Date*: 2013-11-28
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multicenter, prospective, randomized, open label study to assess the effect of serelaxin versus standard of care in acute heart failure (AHF) patients.
    Medical condition: Acute heart failure
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) AT (Prematurely Ended) HU (Prematurely Ended) IT (Prematurely Ended) CZ (Prematurely Ended) SK (Prematurely Ended) BE (Completed) PT (Prematurely Ended) BG (Completed) LT (Completed) PL (Prematurely Ended) LV (Prematurely Ended) EE (Completed) FI (Prematurely Ended) SI (Prematurely Ended) GR (Prematurely Ended) ES (Prematurely Ended) HR (Prematurely Ended) DK (Prematurely Ended) IS (Prematurely Ended) FR (Completed)
    Trial results: View results
    EudraCT Number: 2018-001141-13 Sponsor Protocol Number: GO40516 Start Date*: 2020-02-21
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: AN OPEN-LABEL, RANDOMIZED, MULTICENTER, PHASE Ib/II TRIAL EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF MOSUNETUZUMAB (BTCT4465A) IN COMBINATION WITH POLATUZUMAB VEDOTIN IN...
    Medical condition: B-cell non-Hodgkin lymphoma (NHL)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10067070 Follicular B-cell non-Hodgkin's lymphoma LLT
    20.0 10005329 - Blood and lymphatic system disorders 10025320 Lymphomas non-Hodgkin's B-cell HLGT
    21.0 100000004864 10012820 Diffuse large B-cell lymphoma NOS LLT
    21.1 100000004864 10012856 Diffuse large cell lymphoma (Diffuse large B-cell lymphoma) (Working Formulation) recurrent LLT
    21.1 100000004864 10023768 Large cell immunoblastic lymphoma (Diffuse large B-cell lymphoma) (Working Formulation) recurrent LLT
    21.1 100000004864 10012857 Diffuse large cell lymphoma (Diffuse large B-cell lymphoma) (Working Formulation) refractory LLT
    21.1 100000004864 10023769 Large cell immunoblastic lymphoma (Diffuse large B-cell lymphoma) (Working Formulation) refractory LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) ES (Ongoing) BE (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jun 01 21:01:09 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA